Excessive daytime sleepiness, but not sleep apnea, sleep duration or insomnia, was associated with poor adherence to anti-hypertensive treatment: The ELSA-Brasil study

Imagem de Miniatura
Arquivos
art_AIELO_Excessive_daytime_sleepiness_but_not_sleep_apnea_sleep_2023.PDF (817.97 KB)
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER
Autores
GIATTI, Soraya
Citação
SLEEP MEDICINE, v.104, p.113-120, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Hypertension is the leading risk factor for cardiovascular mortality. Poor adherence may partially explain this scenario. Beyond traditional factors, it is conceivable that sleep conditions such as Obstructive Sleep Apnea (OSA), Sleep Duration (SDUR), sleepiness and insomnia may contribute to impair adherence but the evidence is scanty. Consecutive participants with hypertension from the ELSA-Brasil study performed a home sleep monitoring and 7-days actigraphy to determine OSA (apnea-hypopnea index >= 15 events/ hour) and SDUR, respectively. Excessive daytime sleepiness (EDS) and insomnia were evaluated by Epworth Sleepiness Scale (ESS) and Clinical Interview Scheduled Revised (CIS-R), respectively. The 4itens Morisky questionnaire was used to evaluate adherence to anti-hypertensive therapy. A total of 411 patients were including in the analysis (mean age: 54 +/- 8 years, 47% men). Medium/low adherence to anti-hypertensive therapy was observed in 62%. Compared to the high adherence group, the participants with medium/low adherence had lower frequencies of Whites (64.1 vs. 47.8%), high-degree education (50.6 vs. 40%), and monthly per-capita income ($1021.90 vs. $805.20). In contrast, we observed higher frequency of EDS (35.9 vs. 46.1%). No differences were observed for OSA, short SDUR (<6 h) and insomnia. Logistic regression analysis showed that race other than White (OR: 1.80; 95% IC:1.15-2.82), lower monthly income (OR: 1.74; 95% IC:1.01-3.0) and EDS (OR: 1.63; 95% IC:1.05-2.53) were independently associated with medium/low adherence to the anti-hypertensive treatment. Interestingly, EDS mediated the abdominal obesity-adherence outcome. In conclusion, among sleep-related parameters, EDS, but not OSA, short SDUR or insomnia, were associated to impaired adherence to anti-hypertensive therapy.(c) 2023 Elsevier B.V. All rights reserved.
Palavras-chave
Sleep apnea, Sleep duration, Medication adherence, Hypertension
URI
https://observatorio.fm.usp.br/handle/OPI/53772
Referências
  1. Abegaz TM, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005641
  2. Aielo AN, 2019, SLEEP SCI, V12, P65, DOI 10.5935/1984-0063.20190072
  3. Aquino EML, 2012, AM J EPIDEMIOL, V175, P315, DOI 10.1093/aje/kwr294
  4. Ben AJ, 2012, REV SAUDE PUBL, V46, P279, DOI 10.1590/S0034-89102012005000013
  5. Bensenor IM., 2013, REV SAUDE PUBL, V47, P37, DOI [10.1590/S0034-8910, DOI 10.1590/S0034-8910.2013047003780, 10.1590/S0034-8910.2013047003780]
  6. Berry RB, 2012, J CLIN SLEEP MED, V8, P597, DOI 10.5664/jcsm.2172
  7. Bertolazi AN, 2009, J BRAS PNEUMOL, V35, P877, DOI 10.1590/S1806-37132009000900009
  8. Brownlow JA, 2020, SLEEP MED CLIN, V15, P71, DOI 10.1016/j.jsmc.2019.10.002
  9. Butler MJ, 2017, J AM SOC HYPERTENS, V11, P581, DOI 10.1016/j.jash.2017.06.011
  10. Buysse DJ, 2013, JAMA-J AM MED ASSOC, V309, P706, DOI 10.1001/jama.2013.193
  11. Choudhry NK, 2022, HYPERTENSION, V79, pE1, DOI 10.1161/HYP.0000000000000203
  12. Chow CK, 2013, JAMA-J AM MED ASSOC, V310, P959, DOI 10.1001/jama.2013.184182
  13. Chowdhuri S, 2016, AM J RESP CRIT CARE, V193, pE37, DOI 10.1164/rccm.201602-0361ST
  14. Drager LF, 2020, SLEEP SCI, V13, P94, DOI 10.5935/1984-0063.20200028
  15. Drager LF, 2019, CHEST, V155, P1190, DOI 10.1016/j.chest.2018.12.003
  16. Duncan BB., 2011, HCPA
  17. Fernandez-Mendoza J, 2015, SLEEP, V38, P351, DOI 10.5665/sleep.4488
  18. Friedman O, 2010, AM J MED, V123, P173, DOI 10.1016/j.amjmed.2009.08.008
  19. Gandhi KD, 2021, MAYO CLIN PROC, V96, P1288, DOI 10.1016/j.mayocp.2020.08.033
  20. Gniwa Omezzine Rim, 2019, Tunis Med, V97, P564
  21. Gupta P, 2017, HYPERTENSION, V69, P1113, DOI 10.1161/HYPERTENSIONAHA.116.08729
  22. Heinzer R, 2015, LANCET RESP MED, V3, P310, DOI 10.1016/S2213-2600(15)00043-0
  23. Hirshkowitz M, 2015, SLEEP HEALTH, V1, P233, DOI 10.1016/j.sleh.2015.10.004
  24. Holmes HM, 2012, J AM GERIATR SOC, V60, P1298, DOI 10.1111/j.1532-5415.2012.04037.x
  25. JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540
  26. Khalesi S, 2017, HIGH BLOOD PRESS CAR, V24, P453, DOI 10.1007/s40292-017-0229-9
  27. Krousel-Wood M, 2011, HYPERTENSION, V58, P804, DOI 10.1161/HYPERTENSIONAHA.111.176859
  28. Lauffenburger JC, 2014, CIRCULATION, V129, P754, DOI 10.1161/CIRCULATIONAHA.113.002658
  29. Lee H, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.013148
  30. Ma YJ, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.13573
  31. Melaku YA, 2019, NUTRIENTS, V11, DOI 10.3390/nu11102374
  32. Melamed S, 2002, SLEEP, V25, P315, DOI 10.1093/sleep/25.3.315
  33. Mill JG, 2019, J CLIN HYPERTENS, V21, P502, DOI 10.1111/jch.13509
  34. Morisky DE, 2008, J CLIN HYPERTENS, V10, P348, DOI 10.1111/j.1751-7176.2008.07572.x
  35. Morrison VL, 2015, VALUE HEALTH, V18, P206, DOI 10.1016/j.jval.2014.12.013
  36. Ng SSS, 2010, RESPIROLOGY, V15, P336, DOI 10.1111/j.1440-1843.2009.01697.x
  37. Panossian LA, 2012, SLEEP, V35, P605, DOI 10.5665/sleep.1812
  38. Riegel B, 2011, J CARD FAIL, V17, P340, DOI 10.1016/j.cardfail.2010.11.002
  39. Righi CG, 2017, J CLIN HYPERTENS, V19, P534, DOI 10.1111/jch.12992
  40. Rolnick SJ, 2013, CLIN MED RES, V11, P54, DOI 10.3121/cmr.2013.1113
  41. Roshi D, 2021, E MEDITERR HEALTH J, V27, P516, DOI 10.26719/emhj.21.008
  42. Santos RB., 2021, SLEEP EPIDEMIOL, V1, P100013, DOI [10.1016/J.SLEEPE.2021.100013, DOI 10.1016/J.SLEEPE.2021.100013]
  43. Schmidt MI, 2015, INT J EPIDEMIOL, V44, P68, DOI 10.1093/ije/dyu027
  44. Silva WA, 2021, SLEEP BREATH, V25, P1935, DOI 10.1007/s11325-021-02290-7
  45. Souza SP, 2021, ARTERIOSCL THROM VAS, V41, P1549, DOI 10.1161/ATVBAHA.120.315644
  46. Stewart R, 2006, SLEEP, V29, P1391, DOI 10.1093/sleep/29.11.1391
  47. Tiihonen P, 2009, TELEMED J E-HEALTH, V15, P283, DOI 10.1089/tmj.2008.0118
  48. Tingley D, 2014, J STAT SOFTW, V59
  49. Tufik S, 2010, SLEEP MED, V11, P441, DOI 10.1016/j.sleep.2009.10.005
  50. Uchmanowicz B, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00168
  51. Uchoa CHG, 2017, CHEST, V152, P1230, DOI 10.1016/j.chest.2017.08.003
  52. Vanek J, 2020, SLEEP MED, V72, P50, DOI 10.1016/j.sleep.2020.03.017
  53. Vgontzas AN, 1998, ARCH INTERN MED, V158, P1333, DOI 10.1001/archinte.158.12.1333
  54. Virani SS, 2021, CIRCULATION, V143, pe254, DOI 10.1161/CIR.0000000000000950
  55. Williams NJ, 2014, PATIENT PREFER ADHER, V8, P283, DOI 10.2147/PPA.S53617

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - HU
Artigos e Materiais de Revistas Científicas - LIM/20
Artigos e Materiais de Revistas Científicas - LIM/63
Carregar mais